BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21811504)

  • 1. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
    Fathi AT; Abdel-Wahab O
    Adv Hematol; 2012; 2012():469592. PubMed ID: 21811504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mutations in epigenetic regulators in myeloid malignancies.
    Shih AH; Abdel-Wahab O; Patel JP; Levine RL
    Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosine modifications in myeloid malignancies.
    Meldi KM; Figueroa ME
    Pharmacol Ther; 2015 Aug; 152():42-53. PubMed ID: 25956466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Epigenetic Modifications in Myeloid Malignancies.
    Venney D; Mohd-Sarip A; Mills KI
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significance of the epigenetics modifying gene mutations in acute myeloid leukemia].
    Wakita S; Yamaguchi H
    Nihon Rinsho; 2014 Jun; 72(6):1026-32. PubMed ID: 25016799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
    Castelli G; Pelosi E; Testa U
    Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research on molecular markers for epigenetic changes in myeloid malignancies].
    Li L; Sun XM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of novel mutations in epigenetic modifiers in AML.
    Abdel-Wahab O; Patel J; Levine RL
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic alterations in hematopoietic malignancies.
    Chung YR; Schatoff E; Abdel-Wahab O
    Int J Hematol; 2012 Oct; 96(4):413-27. PubMed ID: 23015417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
    Kim TK; Gore SD; Zeidan AM
    Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.
    Sorrentino VG; Thota S; Gonzalez EA; Rameshwar P; Chang VT; Etchegaray JP
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
    Bewersdorf JP; Shallis R; Stahl M; Zeidan AM
    Ther Adv Hematol; 2019; 10():2040620718816698. PubMed ID: 30719265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in epigenetic regulators in myelodysplastic syndromes.
    Nikoloski G; van der Reijden BA; Jansen JH
    Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.